CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Open Access
- 29 May 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Neuroinflammation
- Vol. 9 (1), 112
- https://doi.org/10.1186/1742-2094-9-112
Abstract
Background: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). In the murine experimental autoimmune encephalomyelitis (EAE) model of MS, T regulatory (Treg) cell therapy has proved to be beneficial, but generation of stable CNS-targeting Tregs needs further development. Here, we propose gene engineering to achieve CNS-targeting Tregs from naive CD4 cells and demonstrate their efficacy in the EAE model. Methods: CD4(+) T cells were modified utilizing a lentiviral vector system to express a chimeric antigen receptor (CAR) targeting myelin oligodendrocyte glycoprotein (MOG) in trans with the murine FoxP3 gene that drives Treg differentiation. The cells were evaluated in vitro for suppressive capacity and in C57BL/6 mice to treat EAE. Cells were administered by intranasal (i.n.) cell delivery. Results: The engineered Tregs demonstrated suppressive capacity in vitro and could efficiently access various regions in the brain via i.n cell delivery. Clinical score 3 EAE mice were treated and the engineered Tregs suppressed ongoing encephalomyelitis as demonstrated by reduced disease symptoms as well as decreased IL-12 and IFNgamma mRNAs in brain tissue. Immunohistochemical markers for myelination (MBP) and reactive astrogliosis (GFAP) confirmed recovery in mice treated with engineered Tregs compared to controls. Symptom-free mice were rechallenged with a second EAE-inducing inoculum but remained healthy, demonstrating the sustained effect of engineered Tregs. Conclusion: CNS-targeting Tregs delivered i.n. localized to the CNS and efficiently suppressed ongoing inflammation leading to diminished disease symptoms.Keywords
This publication has 39 references indexed in Scilit:
- Human ROR gamma t(+) T(H)17 cells preferentially differentiate from naive FOXP3(+)Treg in the presence of lineage-specific polarizing factorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damagePediatric Research, 2010
- T regulatory cells lacking CD25 are increased in MS during relapseAutoimmunity, 2010
- Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritisProceedings of the National Academy of Sciences of the United States of America, 2009
- FOXP3 and the regulation of Treg/Th17 differentiationMicrobes and Infection, 2009
- Intranasal delivery of cells to the brainEuropean Journal of Cell Biology, 2009
- Compromised CD4+ CD25high regulatory T‐cell function in patients with relapsing‐remitting multiple sclerosis is correlated with a reduced frequency of FOXP3‐positive cells and reduced FOXP3 expression at the single‐cell levelImmunology, 2007
- Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammationNature Medicine, 2007
- Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vectorNature Biotechnology, 2004
- Immunological Aspects of Experimental Allergic Encephalomyelitis and Multiple SclerosisCritical Reviews in Clinical Laboratory Sciences, 1995